Adjuvant surgical resection for nontuberculous mycobacterial pulmonary disease: Effectiveness and complications

被引:0
|
作者
Kim, Ji Yong [1 ]
Yun, Jae Kwang [1 ]
Lee, Geon Dong [1 ]
Choi, Sehoon [1 ]
Kim, Hyeong Ryul [1 ]
Kim, Yong-Hee [1 ]
Park, Seung-Il [1 ]
Kim, Dong Kwan [1 ]
机构
[1] Univ Ulsan, Div Thorac Surg, Dept Thorac & Cardiovasc Surg, Asan Med Ctr,Coll Med, Seoul, South Korea
关键词
Complication; nontuberculous mycobacteria pulmonary disease; pulmonary resection; recurrence; LUNG-DISEASE; PNEUMONECTOMY; SURGERY;
D O I
10.4103/atm.atm_237_23
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Standard antibiotic treatment for nontuberculous mycobacteria pulmonary disease (NTMPD) has unsatisfactory success rates. Pulmonary resection is considered adjunctive therapy for patients with refractory disease or severe complications, but surgical indications and extent of resection remain unclear. We present surgical treatment outcomes for NTMPD and analyzes risk factors for unfavorable outcomes. METHODS: We conducted a retrospective investigation of medical records for patients diagnosed with NTMPD who underwent surgical treatment at Asan Medical Center between 2007 and 2021. We analyzed clinical data including microbiological and surgical outcomes. RESULTS: A total of 71 NTMPD patients underwent thoracic surgery. Negative conversion of acid-fast bacillus (AFB) culture following pulmonary resection was observed in 51 (73.9%) patients. In terms of long-term outcomes, negative conversion was sustained in 38 cases (55.1%). Mortality occurred in 7 patients who underwent pulmonary resections for NTMPD. Statistically significant associations with factors for recurrence or non-negative conversion of AFB culture were found in older age (odds ratio [OR] =1.093, 95% confidence interval [CI]: 1.029-1.161, P = 0.004), male sex (OR = 0.251, 95% CI: 0.071-0.892, P = 0.033), and extensive NTMPD lesions involving three lobes or more (OR = 5.362, 95% CI: 1.315-21.857, P = 0.019). Interstitial lung disease (OR = 13.111, 95% CI: 1.554-110.585, P = 0.018) and pneumonectomy (OR = 19.667, 95% CI: 2.017-191.797, P = 0.018) were statistically significant risk factors for postoperative mortality. CONCLUSION: Pulmonary resection can be an effective adjuvant treatment option for NTMPD patients, with post-operative antibiotic treatment as the primary treatment. Careful patient selection is crucial, considering the associated risk factors and resectability due to complications and recurrence.
引用
收藏
页码:131 / 138
页数:8
相关论文
共 50 条
  • [21] Surgical treatment of nontuberculous mycobacterial lung disease
    Shiraishi Y.
    General Thoracic and Cardiovascular Surgery, 2014, 62 (8) : 475 - 480
  • [22] Occupational Exposures in Nontuberculous Mycobacterial Pulmonary Disease
    Blanc, Paul D.
    Balmes, John R.
    Redlich, Carrie
    CHEST, 2022, 162 (02) : E106 - E107
  • [23] Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan
    Namkoong, Ho
    Kurashima, Atsuyuki
    Morimoto, Kozo
    Hoshino, Yoshihiko
    Hasegawa, Naoki
    Ato, Manabu
    Mitarai, Satoshi
    EMERGING INFECTIOUS DISEASES, 2016, 22 (06) : 1116 - 1117
  • [24] The fungal burden in nontuberculous mycobacterial pulmonary disease
    Kumar, K.
    Nastase, A.
    Cuthbertson, L.
    Ellis, H. C.
    Loebinger, M. R.
    Moffatt, M. F.
    Cookson, W. O. C.
    THORAX, 2023, 78 (SUPPL_4) : A105 - A106
  • [25] The lung microbiota in nontuberculous mycobacterial pulmonary disease
    Kim, Bo-Guen
    Kang, Noeul
    Kim, Su-Young
    Kim, Dae Hun
    Kim, Hojoong
    Kwon, O. Jung
    Huh, Hee Jae
    Lee, Nam Yong
    Jhun, Byung Woo
    PLOS ONE, 2023, 18 (05):
  • [26] Diagnosis and evaluation of nontuberculous mycobacterial pulmonary disease
    Kim, Hyung-Jun
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2024, 67 (01): : 12 - 18
  • [27] Immunologic signatures of nontuberculous mycobacterial pulmonary disease
    Kwak, Nakwon
    Koh, Jaemoon
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [28] THE LUNG MICROBIOME IN NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE
    Kumar, K.
    Cuthbertson, L.
    Ellis, H. C.
    Churchward, C.
    Loebinger, M. R.
    Moffatt, M. F.
    Cookson, W. O. C.
    THORAX, 2022, 77 : A36 - A36
  • [29] Nonpharmacological Treatment for Nontuberculous Mycobacterial Pulmonary Disease
    Kim, Hyung-Jun
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2024, 87 (04) : 451 - 457
  • [30] Current Therapy for Nontuberculous Mycobacterial Pulmonary Disease
    Hilary P. Steele
    Lisa M. Brumble
    Margaret M. Johnson
    Current Treatment Options in Infectious Diseases, 2015, 7 (4) : 342 - 351